XNAS · CMPX
+0.43% · +$0.0100 · Vol 2.8M
Market closed · last close 4:00 PM ET · price as of 16:55:23 ET
Compass Therapeutics, Inc. Common Stock

Compass Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$2.32
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
HISTORY WINDOW BUILDING
AI Analysis
Sovereign

Why is CMPX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for CMPX are being assembled.
About Compass Therapeutics, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
39
Country
US

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.30
Day high
$2.36
Day low
$2.19
Previous close
$2.31
52W high
$2.36
-1.69% from high
52W low
$2.19
76% of range
Market cap
$416M
EPS
$-0.1000
Shares out
180.1M
Volume
2.8M
VWAP
$2.27
Price history computed in-house
SMA 50 $2.33 · below
SMA 200 $2.33 · below
52W position 76%
Veridion warehouse edge

Warehouse intelligence for CMPX.

Veridion Score
60
0: 871: 392: 203: 654: 835: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

CMPX insider activity

Compass Therapeutics, Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for CMPX.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

CMPX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CMPX in this window.
Lobbying spend

CMPX lobbying filings, year to date.

Registered lobbying filings matched to Compass Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CMPX in this window.
Latest news · CMPX
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for CMPX.
Options
Sovereign unlock shows live options positioning for CMPX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.